Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib [Rapid Communication]

Conclusion
pCR to dual HER2-targeted therapy was not significantly higher than single HER2 targeting. Tissue analysis demonstrated a high degree of intertumoral heterogeneity with respect to both tumor genomics and tumor microenvironment that significantly affected pCR rates. These factors should be considered when interpreting and designing trials in HER2-positive disease.

Source: Journal of Clinical Oncology - February 9, 2016 Category: Cancer & Oncology Authors: Carey, Berry, Cirrincione, Barry, Pitcher, Harris, Ollila, Krop, Henry, Weckstein, Anders, Singh, Hoadley, Iglesia, Cheang, Perou, Winer, Hudis Tags: Combined Modality, Translational Oncology Rapid Communication Source Type: research